APA (7th ed.) Citation

M, G., M, S., T, M., N, R., R, C., A, A. H., . . . D, B. (2026). Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): Phase Ib-II VENEZOLUNG trial. Journal for immunotherapy of cancer, 14(7), . https://doi.org/10.1136/jitc-2026-015351

Chicago Style (17th ed.) Citation

M, Gonzalez-Cao, et al. "Personalized Tumor-loaded Monocyte-derived Dendritic Cell Vaccination in Combination with Atezolizumab as Maintenance Treatment in Extensive-stage Small Cell Lung Cancer (ES-SCLC): Phase Ib-II VENEZOLUNG Trial." Journal for Immunotherapy of Cancer 14, no. 7 (2026). https://doi.org/10.1136/jitc-2026-015351.

MLA (9th ed.) Citation

M, Gonzalez-Cao, et al. "Personalized Tumor-loaded Monocyte-derived Dendritic Cell Vaccination in Combination with Atezolizumab as Maintenance Treatment in Extensive-stage Small Cell Lung Cancer (ES-SCLC): Phase Ib-II VENEZOLUNG Trial." Journal for Immunotherapy of Cancer, vol. 14, no. 7, 2026, https://doi.org/10.1136/jitc-2026-015351.